Carlos Alvarez-Fernandez

3PUBLICATIONS
29CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Apr 29, 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández

|Nov 14, 2023
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.

María José Juan Fita, Urbano Anido Herranz, María José Mendez-Vidal

|Dec 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.

Thomas Powles, Srikala S Sridhar, Yohann Loriot

Pageof 1

Frequent Collaborators

1 joint publications

Thomas Powles

1 joint publications

Joaquim Bellmunt

1 joint publications

Petros Grivas

1 joint publications

Craig B Davis